TRP Channels as Therapeutic Targets: From Basic Science to Clinical Use is authored by experts across academia and industry, providing readers with a complete picture of the therapeutic potential and challenges associated with using TRP channels as drug targets.
This book offers a unique clinical approach by covering compounds that target TRP channels in pre-clinical and clinical phases, also offering a discussion of TRP channels as biomarkers.
An entire section is devoted to the novel and innovative uses of these channels across a variety of diseases, offering strategies that can be used to overcome the adverse effects of first generation TRPV1 antagonists.
Intended for all researchers and clinicians working toward the development of successful drugs targeting TRP channels, this book is an essential resource chocked full of the latest clinical data and findings.
- Contains comprehensive coverage of TRP channels as therapeutic targets, from emerging clinical indications to completed clinical trials
- Discusses TRP channels as validated targets, ranging from obesity and diabetes through cancer and respiratory disorders, kidney diseases, hypertension, neurodegenerative disorders, and more
- Provides critical analysis of the complications and side effects that have surfaced during clinical trials, offering evidence-based suggestions for overcoming them
TRP Channels as Therapeutic Targets: From Basic Science to Clinical Use is authored by experts across academia and industry, providing readers with a complete picture of the therapeutic potential and challenges associated with using TRP channels as drug targets. This book offers a unique clinical approach by covering compounds that target TRP channels in pre-clinical and clinical phases, also offering a discussion of TRP channels as biomarkers. An entire section is devoted to the novel and innovative uses of these channels across a variety of diseases, offering strategies that can be used to overcome the adverse effects of first generation TRPV1 antagonists. Intended for all researchers and clinicians working toward the development of successful drugs targeting TRP channels, this book is an essential resource chocked full of the latest clinical data and findings. Contains comprehensive coverage of TRP channels as therapeutic targets, from emerging clinical indications to completed clinical trials Discusses TRP channels as validated targets, ranging from obesity and diabetes through cancer and respiratory disorders, kidney diseases, hypertension, neurodegenerative disorders, and more Provides critical analysis of the complications and side effects that have surfaced during clinical trials, offering evidence-based suggestions for overcoming them
Contributors
M. Allen McAlexander Neuronal Targets Team, Respiratory Therapy Area, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania, USA
Ganesan Baranidharan Consultant in Pain Medicine, Leeds Teaching Hospitals NHS trust: D ward, Seacroft Hospital, Leeds, LS14 6UH
Ralf Baron Division of Neurological Pain Research and Therapy, Department of Neurology, University Hospital Schleswig-Holstein, Kiel, Germany
Arun K. Bhaskar Consultant in Pain Medicine, Leeds Teaching Hospitals NHS trust: D ward, Seacroft Hospital, Leeds, LS14 6UH
Mahendra Bishnoi Department of Nutritional Sciences, and Technology, National Agri-Food Biotechnology Institute (NABI), SAS Nagar, India
Jill-Desiree Brederson Global Medical Communications, Research and Development, AbbVie Inc., North Chicago, Illinois, USA
Dorothy Cimino Brown Veterinary Clinical Investigations Center and Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
Nigel W. Bunnett Monash Institute of Pharmaceutical Sciences, and Department of Pharmacology, The University of Melbourne, Parkville, Victoria, Australia
Ingolf Cascorbi Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Kiel, Germany
Michael J. Caterina
Department of Neurosurgery
Department of Biological Chemistry
Solomon H. Snyder Department of Neuroscience and Neurosurgery Pain Research Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
Ana Charrua
IBMC—Instituto de Biologia Molecular e Celular da Universidade do Porto
Departamento de Urologia, Faculdade de Medicina da Universidade do Porto and Departamento de Doenças Renais, Urológicas e Infecciosas, Faculdade de Medicina da Universidade do Porto, Porto, Portugal
Francisco Cruz
IBMC—Instituto de Biologia Molecular e Celular da Universidade do Porto
Departamento de Urologia, Faculdade de Medicina da Universidade do Porto
Departamento de Doenças Renais, Urológicas e Infecciosas, Faculdade de Medicina da Universidade do Porto and Departamento de Urologia, Hospital São João, Porto, Portugal
Matthew A.J. Duncton Renovis, Inc. (a wholly owned subsidiary of Evotec AG), South San Francisco, California, USA
Madeleine Ennis Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland, UK
Susan Fleetwood-Walker Centre for Integrative Physiology, School of Biomedical Sciences, College of Medicine & Veterinary Medicine, University of Edinburgh, Scotland, UK
Ehud Goldin SENS Research Foundation, Mountain View, CA, USA
Arthur Gomtsyan Department of Chemistry, Research and Development, AbbVie Inc., North Chicago, Illinois, USA
Huizhen Huang
Department of Neurobiology, University of Pittsburgh
Pittsburgh Center for Pain Research, Pittsburgh, PA, USA, and Tsinghua University School of Medicine, Beijing, China
Gerald Hunsberger Neuronal Targets Team, Respiratory Therapy Area, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania, USA
Michael J. Iadarola Anesthesia Section, Department of Perioperative Medicine, Clinical Center, NIH, Bethesda, Maryland, USA
Neelima Khairatkar Joshi Glenmark Research Centre, Navi Mumbai, Glenmark Pharmaceuticals Ltd, India
Pragyanshu Khare Department of Nutritional Sciences and Technology, National Agri-Food Biotechnology Institute (NABI), SAS Nagar, India
Kirill Kiselyov Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA, USA
Ari Koivisto Research and Development, OrionPharma, Orion Corporation, Turku, Finland
Kanthi K. Kondepudi Department of Food Sciences and Technology, National Agri-Food Biotechnology Institute (NABI), SAS Nagar, India
Artem Kondratskyi Inserm U-1003, Equipe labellisée par la Ligue Nationale contre le cancer, Laboratory of Excellence Ion Channels Science and Therapeutics, Université Lille 1, Villeneuve d’Ascq, France
Ina Kraus-Stojanowic Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig-Holstein, Kiel, Germany
TinaMarie Lieu Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia
Daoyan Liu Department of Hypertension and Endocrinology, Center for Hypertension and Metabolic Diseases, Daping Hospital, Third Military Medical University, Chongqing Institute of Hypertension, Chongqing, China
Nancy Luo Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA
Lorcan McGarvey Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland, UK
Rory Mitchell Centre for Integrative Physiology, School of Biomedical Sciences, College of Medicine & Veterinary Medicine, University of Edinburgh, Scotland, UK
Magdalene Moran Hydra Biosciences Cambridge, MA, USA
Christopher Neipp Flexible Discovery Unit, GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania, USA
Bernd Nilius Katholieke Universiteit of Leuven, Department of Cellular and Molecular Medicine, Laboratory of Ion Channel Research and TRP Research Platform Leuven (TRPLe), Campus Gasthuisberg, Leuven, Belgium
James C. Parker Department of Physiology and Center for Lung Biology, University of South Alabama, Mobile, Alabama, USA
Antti Pertovaara Institute of Biomedicine/Physiology, University of Helsinki, Helsinki, Finland
Koenraad Philippaert Katholieke Universiteit of Leuven, Department of Cellular and Molecular Medicine, Laboratory of Ion Channel Research and TRPLe (TRP Research Platform Leuven), Campus Gasthuisberg, Leuven, Belgium
Daniel P. Poole
Monash Institute of Pharmaceutical Sciences
Department of Anatomy & Cell Biology, The University of Melbourne, Parkville, Victoria, Australia
Louis S. Premkumar Department of Pharmacology, Southern Illinois University-School of Medicine, Springfield, Illinois, USA
Natalia Prevarskaya Inserm U-1003, Equipe labellisée par la Ligue Nationale contre le cancer, Laboratory of Excellence Ion Channels Science and Therapeutics, Université Lille 1, Villeneuve d’Ascq, France
Pradeep Rajasekhar Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia
Paul Rosenberg Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA
Sarah E. Ross
Department of Neurobiology
Department of Anesthesiology
Pittsburgh Center for Pain Research, and Center for Neuroscience Research at the University of Pittsburgh, Pittsburgh PA, USA
Kavisha Singh Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA
Lindsey M. Snyder
Department of Neurobiology, University of...
Erscheint lt. Verlag | 9.4.2015 |
---|---|
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
Studium ► 1. Studienabschnitt (Vorklinik) ► Physiologie | |
Naturwissenschaften ► Biologie ► Biochemie | |
Naturwissenschaften ► Biologie ► Humanbiologie | |
Naturwissenschaften ► Biologie ► Zoologie | |
ISBN-10 | 0-12-420079-6 / 0124200796 |
ISBN-13 | 978-0-12-420079-1 / 9780124200791 |
Haben Sie eine Frage zum Produkt? |
![PDF](/img/icon_pdf_big.jpg)
Größe: 16,7 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
![EPUB](/img/icon_epub_big.jpg)
Größe: 14,3 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich